Review of Pharmacotherapy in Multiple Sclerosis - July 26, 2023

Explore a comprehensive review of pharmacotherapy options for multiple sclerosis in this 54-minute physician grand rounds presentation. Gain insights into the goals of disease-modifying therapies (DMTs) and factors influencing patient choice. Delve into various treatment options, including interferons, glatiramer acetate, monomethyl fumarate pro-drugs, sphingosine 1 phosphate receptor modulators, and specific medications like teriflunomide, cladribine, natalizumab, ocrelizumab, ofatumumab, and alemtuzumab. Learn about inpatient admission considerations, infection management, vaccination protocols, and malignancy risks associated with MS treatments. Presented by Nancy Le, PharmD, a Clinical Pharmacy Specialist in Adult Neurology and Adjunct Assistant Clinical Professor at the University of Iowa College of Pharmacy, this talk offers valuable knowledge for healthcare professionals managing multiple sclerosis patients.

Intro
Objectives
Goal of Disease Modifying Therapy (DMT)
Factors that impact patient's DMT choice
Interferons
Glatiramer acetate
Monomethyl Fumarate Pro-Drugs
Sphingosine 1 Phosphate Receptor Modulators
Teriflunomide (Aubagio®)
Cladribine (MavencladⓇ)
Natalizumab (Tysabri®)
Ocrelizumab (Ocrevus®)
Ofatumumab (Kesimpta®)
Alemtuzumab (Lemtrada®)
Inpatient admission
Infections and Vaccination
Malignancy
Summary